Výsledky vyhledávání - "B Caballol Oliva"

P118 Inflammatory Bowel Disease Unclassified and Ulcerative Colitis: different outcomes? Multicenter case-control study (Spanish ENEIDA registry)

Publikováno v: Journal of Crohn's and Colitis. 16:i208-i210

Background Patients with inflammatory bowel disease (IBD) are often classified as ulcerative colitis (UC) and Crohn’s disease (CD). However, in some cases this categorization is not possible and these patients are labelled as inflammatory bowel dis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::94c9ff8e40620b76e38da0b61fc8a3ca
https://doi.org/10.1093/ecco-jcc/jjab232.246

Zobrazit plný text záznamu

P383 Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry

Autor: M I Iborra Colomino, A Garrido Marín, B Caballol Oliva, J M Huguet Malavés, L Arias García, F Mesonero Gismero, S J Fernández Prada, M M Boscá Watts, Á Ponferrada Díaz, X Calvet Calvo, A Gutiérrez Casbas, I Ordás Jiménez, L Ruiz Sanchez, B Sicilia Aladren, I Garcia de la Filia, E Domènech Morral, P Nos Mateu

Publikováno v: Journal of Crohn's and Colitis. 17:i517-i518

Background Recently, a subcutaneous formulation of biosimilar infliximab (CT-P13) (SC-IFX) has been approved for inflammatory bowel disease (IBD). The aims of this study were to evaluate efficacy, safety, pharmacokinetics and patient experience follo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c71a5fbe50c93ef27fa5894654b922c0
https://doi.org/10.1093/ecco-jcc/jjac190.0513

Zobrazit plný text záznamu

P488 Switch from intravenous to subcutaneous infliximab in patients with Inflammatory Bowel Disease: efficacy, safety and patients’ acceptance

Autor: B Caballol Oliva, A Fernàndez-Clotet, J Panés, M C Masamunt, M Gallego, R Barastegui, A Vara, À Giner, E Ricart, I Ordás

Publikováno v: Journal of Crohn's and Colitis. 17:i618-i618

Background A new formulation of biosimilar infliximab (IFX) has recently been approved for subcutaneous administration (SC) that may offer pharmacokinetic advantages resulting in higher drug exposure. Our purpose was to evaluate the efficacy, safety,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bb9a9a630d94d259925f448ebf4d7470
https://doi.org/10.1093/ecco-jcc/jjac190.0618

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání